Product Description: MLT-943 is a potent, selective and orally active MALT1 protease inhibitor. MLT-943 inhibits stimulated-IL-2 secretion in PBMC or in whole blood with a similar IC50 across species (0.07-0.09 μM in PBMC, 0.6-0.8 μM in whole blood). MLT-943 has anti-inflammatory activities and can be used for FcgR-mediated inflammation research[1].
Applications: COVID-19-immunoregulation
Formula: C16H14ClF3N6O2
References: [1]Kea Martin, et al. Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology. Front Immunol/[2]Jean Quancard, et al. Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood. J Med Chem. 2020 Dec 10;63(23):14594-14608.
CAS Number: 1832576-04-1
Molecular Weight: 414.77
Compound Purity: 99.77
Research Area: Inflammation/Immunology
Solubility: DMSO : 250 mg/mL (ultrasonic)
Target: MALT1